Literature DB >> 8853179

Polyarteritis nodosa and the antiphospholipid syndrome.

R Schoonjans1, B Van Vlem, S Weyers, F De Keyser, M Praet, J Versieck, A Elewaut.   

Abstract

We report a case of biopsy-proven polyarteritis nodosa (classic type in association with the antiphospholipid syndrome. Medium-sized arteriopathy was confirmed on visceral angiography. Elevated anticardiolipin antibodies were detected before initiating therapy with methylprednisolone and IV pulse cyclophosphamide. Rapid subsidence of symptoms correlated with a gradual normalisation of the erythrocyte sedimentation rate. After 6 months of therapy anticardiolipin antibodies were within normal limits. Only one similar case has been reported so far.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8853179     DOI： 10.1007/bf02230368

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  15 in total

1.  The kidney in periarteritis nodosa.

Authors:  J DAVSON; J BALL; R PLATT
Journal:  Q J Med       Date:  1948-07

Review 2.  Vasculopathy associated with the antiphospholipid antibody syndrome.

Authors:  C A Bowles
Journal:  Rheum Dis Clin North Am       Date:  1990-05       Impact factor: 2.670

Review 3.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

4.  Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; M E Pérez-Vázquez; A R Villa; C Drenkard; J Cabiedes
Journal:  Semin Arthritis Rheum       Date:  1992-04       Impact factor: 5.532

5.  Well-imaged large vessel vasculitis attributed to anticardiolipin antibody.

Authors:  W N Roberts; J H DeMeo; S A Breitbach
Journal:  Arthritis Rheum       Date:  1994-08

6.  The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis.

Authors:  L Bleil; B Manger; T H Winkler; M Herrman; G R Burmester; F E Krapf; J R Kalden
Journal:  J Rheumatol       Date:  1991-08       Impact factor: 4.666

7.  Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease.

Authors:  R R Buchanan; J R Wardlaw; A G Riglar; G O Littlejohn; M H Miller
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

Review 8.  Hypercoagulable states.

Authors:  R L Nachman; R Silverstein
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

9.  The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa.

Authors:  R W Lightfoot; B A Michel; D A Bloch; G G Hunder; N J Zvaifler; D J McShane; W P Arend; L H Calabrese; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

10.  [Deep venous thrombosis associated with necrotizing vasculitis].

Authors:  F Cofán; A Serra; J Teixidó; J Bonet; J Bonal; R Lauzurica; R Romero; M Monreal; A Caralps
Journal:  Med Clin (Barc)       Date:  1993-12-11       Impact factor: 1.725
View more
  3 in total

Review 1.  Aneurysms in primary antiphospholipid syndrome: a case-based review.

Authors:  Jozélio Freire de Carvalho; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

2.  A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia.

Authors:  Nayef M Kazzaz; Allecia M Wilson; Ruba Kado; Geoffrey D Barnes; Jason S Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08       Impact factor: 4.794

3.  Antiphospholipid antibodies predict progression of abdominal aortic aneurysms.

Authors:  Christina Duftner; Rüdiger Seiler; Christian Dejaco; Iris Chemelli-Steingruber; Harald Schennach; Werner Klotz; Michael Rieger; Manfred Herold; Jürgen Falkensammer; Gustav Fraedrich; Michael Schirmer
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.